Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Z M Shao
Observed names:
Z. Shao,
Zhi-Min Shao,
Zhi-Ming Shao,
Zhibo Shao,
Zhimin Shao
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Huadong Hospital
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Huadong Hospital
ORCID:
0000-0002-4503-148X
Observed ORCID:
0000-0002-4503-148X
OpenAlex ID:
A5132625935
Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.
2026
·
Zhi-Ming Shao
, Peng Ji
, et al.
·
Journal of Clinical Oncology
·
4
First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
2026
·
David W. Cescon
, Tiffany A. Traina
, et al.
·
Journal of Clinical Oncology
·
4
Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).
2026
·
Michael Untch
, Zhimin Shao
, et al.
·
Journal of Clinical Oncology
·
3
Adjuvant capecitabine and trastuzumab for stage IA HER2-positive breast cancer (IRIS-A): A phase II clinical trial.
2026
·
Ruoxi Wang
, Min He
, et al.
·
Journal of Clinical Oncology
·
3
The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study
2026
·
Tao Huang
, Zhimin Fan
, et al.
·
International Journal of Clinical Oncology
·
3
Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer
2026
·
Fang-Lin Zhang
, Shao-Ying Yang
, et al.
·
Molecular Cancer
·
2
Impact of bevacizumab on the efficacy of antibody–drug conjugates as later-line treatment of basal-like immune-suppressed triple-negative breast cancer.
2026
·
Yin Liu
, Fan Yang
, et al.
·
Journal of Clinical Oncology
·
2
Restoring the CD226 in CD8+T cells overcomes TIGIT-refractory immunity in HER2+ breast cancer
2026
·
Liyi Zhang
, Jiaoduan Li
, et al.
·
Cell Death and Disease
PDF
Integrated multi-omics and single-cell analysis of galectins and immune associations in triple-negative breast cancer
2026
·
Peng Ji
, Hongrui Liu
, et al.
·
Translational Oncology
Early identification of PRISm from chest CT: a multimodal for three-class stratification of normal, PRISm, and COPD
2026
·
Yan Mou
, Xueqing Bian
, et al.
·
Frontiers in Radiology
PDF
Landscape of peripheral immune response induced by multimodal thermal therapy combined with chemoimmunotherapy in patients with early-stage HER2-negative breast cancer.
2026
·
Fei-Lin Qu
, Zelu Zhang
, et al.
·
Journal of Clinical Oncology
PDF
Influence of precision treatment with artificial intelligence–assisted subtyping on first-line therapeutic efficacy in HR+/HER2– breast cancer.
2026
·
Wenjuan Zhang
, Tao Sun
, et al.
·
Journal of Clinical Oncology
Subgroup analysis of participants (pts) with HER2 IHC0 in the ASCENT-07 study of sacituzumab govitecan (SG) vs chemotherapy in HR+/ HER2− metastatic breast cancer (mBC).
2026
·
Yeon Hee Park
, Komal L. Jhaveri
, et al.
·
Journal of Clinical Oncology
Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study.
2026
·
Zhi-Ming Shao
, Ruoxi Wang
, et al.
·
Journal of Clinical Oncology
Deciphering tumor metabolites: emerging technologies shaping clinical implications
2026
·
Xiao-Hui Zhu
, Liang Huang
, et al.
·
Trends in cancer
415O First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Patient-reported outcomes (PROs) from TROPION-Breast02
2026
·
P. Schmid
, T.A. Traina
, et al.
·
ESMO Open
PDF
HDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4
2026
·
Jia-Yang Cai
, Yin-Ling Zhang
, et al.
·
Journal of Cancer Research and Clinical Oncology
[Association between molecular typing and prognosis with recurrence pattern in triple-negative breast cancer patients].
2026
·
Z J Chen
, L J Dai
, et al.
·
PubMed
Show more works
View as search
Works count:
18
Citation count:
21
H-index:
3
I10-index:
Year
Topic
Type